Potential new antibiotic for treating gonorrhoea
Scientists believe they have found a new effective antibiotic for gonorrhoea, which could be one of the most promising in decades. Gepotidacin can treat and clear the sexually transmitted infection just as well as existing antibiotics and appears to be able to tackle some emerging drug-resistant 'superbug' strains too, say researchers in The Lancet journal. The work was funded by pharmaceutical company GSK which makes the new tablets. Gonorrhoea is one of the most common STIs in the UK and cases have been rising.
In 2023, over 85,000 gonorrhoea diagnoses were reported in England alone - the highest number since records began in 1918. Most of the cases were treatable, but there is growing concern that some strains can't be dealt with so easily.Over time, the bacterium has developed resistance to most classes of available antibiotics and experts fear it may become untreatable in the future, unless new drugs are found. Untreated gonorrhoea can lead to serious health issues, including pelvic inflammatory disease and infertility.
Gepotidacin works differently to other antibiotics and stops gonorrhoea from replicating by blocking two essential enzymes. It's already approved in the US for treating urinary tract infections. The trial, being presented at the ESCMID conference, involved 628 patients randomly allocated to receive gepotidacin or an existing antibiotic. The new pill was equally effective for treating gonorrhoea and worked against strains of the infection that were resistant to current first-line treatments, such as ceftriaxone. Side-effects were reported more frequently with gepotidacin, but they were generally mild, such as nausea or some stomach discomfort.
Gepotidacine is not the only new oral antibiotic for gonorrhoea that researchers are exploring. Another, called zoliflodacin, has also shown promise in phase 3 clinical trials. Meanwhile, the UK is considering a vaccine to help stop the spread of gonorrhoea.In November 2023, the Joint Committee on Vaccination and Immunisation (JCVI) recommended a targeted roll-out of the MenB vaccine.Primarily designed to tackle Meningitis B in children, the JCVI found the treatment was roughly 40% effective at preventing people from contracting and spreading gonorrhoea.
Dr Katy Sinka, consultant epidemiologist and head of the STI section at UK Health Security Agency, said it was "really promising" to see a successful trial for a new antibiotic to treat gonorrhoea."As gonorrhoea becomes increasingly resistant to antibiotics, it could become untreatable in future and cause serious problems like pelvic inflammatory disease and infertility. Trials like this are so important to help us discover new treatment options."She said the best way to prevent an STI is by using a condom. If someone has had condom-less sex with a new or casual partner, they should get tested. "Early detection not only protects a person's health but prevents transmission to others. Testing is quick, free and confidential," she said.
Gonorrhoea: quick facts
Gonorrhoea is easily passed from person to person through unprotected sexAround one in 10 infected men and almost half of infected women do not experience any symptomsThe infection can be passed from a pregnant woman to her baby, and without treatment, can cause permanent blindness for a newborn babyIt is not spread by non-sexual contact like huggingIt is not transmitted through surfaces and materials like toilet seats, towels, cups or platesIf you've had successful treatment for gonorrhoea before, you can still catch it againSource: NHSMore information and advice is available on this NHS webpage.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
a day ago
- Daily Mail
Subtle warning signs of 'silent disease' 16m Americans are living with and don't know
Nearly 16 million people have the most deadly type of liver disease, yet 80 percent of them have no idea. About five percent of adults worldwide have metabolic dysfunction-associated steatohepatitis (MASH) a serious liver condition caused by fat buildup, inflammation, and scarring. It's the most dangerous type of fatty liver disease MASH triggers liver scarring, which can progress to cirrhosis, and significantly increases the risk of heart disease, chronic kidney disease, and liver cancer. Just one in five Americans with the condition are actually diagnosed. Most patients do not experience symptoms until the damage is irreversible, making it a 'silent disease'. However, as the condition progresses, individuals may experience fatigue, pain or discomfort in the upper right belly, unexplained weight loss, weakness, and in some cases, jaundice (yellowing of the skin and eyes). A coalition of researchers from the US, Europe, and South Africa said that MASH-related liver failure and other complications, including deaths, are becoming more severe and common. The scientists behind the report, published in The Lancet Regional Health Europe, are calling for a doubling in MASH diagnosis rates from the 2022 level, about 13 percent (the current rate is just under 20 percent). They estimated that about 2.6 million people in the US, UK, Germany, and France have been diagnosed with MASH. But if testing were adequately improved and scaled up to become more accessible and commonplace, that figure could balloon to 6.1 million. People with type 2 diabetes, obesity, and heart disease should be prioritized for blood work and other screening tests, which will need to skyrocket from about two million to 36 million. Follow-up testing also needs to jump by nearly 1,300 percent to meet patient needs, and in more settings than liver clinics, such as family doctors' offices, and with diabetes and heart doctors. People with diabetes are especially prone to liver damage leading to MASH. Around 30 to 60 percent of diabetics also have MASH. Obesity is another leading risk factor, with estimates suggesting that 75 percent of overweight people and 90 percent with obesity will develop the condition. People with MASH also have a tripled risk of also developing heart disease, including coronary artery disease, stroke, and heart failure, compared to people without the condition. MASH diagnosis is poised for a major shift, mirroring past breakthroughs in chronic disease management. With new treatments approved and others on the horizon, the focus now turns to fixing systemic roadblocks. Currently, limited access to non-invasive tests and reliance on specialists leave most cases undetected until late stages. MASH arises from a cascade of liver damage typically linked to a buildup of fat in the liver, which triggers inflammation that damages liver cells and activates scar-forming cells. What was once healthy liver tissue becomes stiff, progressively crippling the liver's ability to detoxify blood. Though this is often painless until the damage becomes too severe to be reversed. If caught early, people can live normal lifespans with MASH. Lifestyle changes - eating a healthier diet, exercising regularly, and losing between five and 10 percent of one's body weight - can slow down the progression of MASH and repair some of the damage. Doctors may prescribe resmetirom, the first FDA-approved medication for MASH, to work hand-in-hand with those lifestyle changes. But severe damage can cause deadly conditions that cut a person's life drastically short. 'Each late-stage MASH diagnosis represents a missed opportunity for earlier intervention to prevent disease progression, threatening worse [liver] and [non-liver] outcomes for people living with the condition and greater costs for individuals, health systems, and societies,' researchers told a Barcelona medical conference this week. The solution requires concrete changes from moving diagnostics to implementing automated tools in electronic records. The researchers said that success in improving diagnostics goes beyond devising better tests. A fundamental reworking of methods of care is needed that catches at-risk patients before irreversible damage occurs. 'Paradigm shifts do not occur in a vacuum, but arise when leaps in science, technology, and innovation are coupled with changes in perception and understanding within a community,' they said. 'A confluence of factors in 2024 and expected drug approvals in many European countries in 2025 point to a near term tipping point for MASH diagnoses; nonetheless, focused and sustained efforts are needed to turn such opportunities into reality.'
BBC News
a day ago
- BBC News
Gonorrhoea vaccinations to start in Northern Ireland in August
The Department of Health has said a targeted vaccination programme against gonorrhoea has been approved across Northern Ireland. Eligible patients will be offered the vaccine from August 2025, the department said. Those eligible include gay and bisexual men who have a recent history of multiple sexual partners or have recently had a sexually transmitted infection (STI). Gonorrhoea is now the most prevalent STI diagnosed in sexual health clinics in Northern Ireland, according to the Public Health Agency (PHA). England will also begin its vaccination roll out in August this vaccine roll out will also focus mainly on gay and bisexual men with a history of multiple sexual partners or an was given by the Joint Committee on Vaccination and Immunisation (JCVI) in November 2023, which recommended roll out of the vaccine following an upsurge in gonorrhoea Minister Mike Nesbitt said the launch of the vaccine programme is "important and very timely for Northern Ireland's public health". He added that by targeting those "most at risk", there is an "opportunity to curb the spread and reduce transmission rates". The vaccine is an existing one for meningococcal B disease, called 4CMenB. The UK Health Security Agency (UKHSA) research shows that those who receive the jab could be protected from the STI by up to 40% and it could help tackle levels of antibiotic-resistant strains of the disease. Record number of gonorrhoea cases PHA figures for Northern Ireland show that between 2021 and 2022 the number of cases jumped from 652 to 1,606 - the highest number recorded by the were 951 cases in 2019, but that dropped to 455 in 2020, likely due to changes in behaviour and healthcare associated with the Covid 2023, there were 1,561 new cases, accounting for almost a third (28%) of all new STI diagnoses in Northern Ireland. Of those diagnosed, 75% were males and of those 67% were gay, bisexual and men who have sex with does not always have symptoms, but they can include pain, unusual discharge, inflammation of the genitals and infertility. The chief medical officer said the vaccine roll-out will have "significant public health benefits for both those who receive the vaccine, and the wider population".Sir Michael McBride said the programme has "the potential to result in less patients presenting with more complex cases and clusters of gonorrhoea".He encouraged all those eligible to take up the vaccine when offered. What is gonorrhoea? Gonorrhoea is easily passed from person to person through unprotected one in 10 infected men and almost half of infected women do not experience any infection can be passed from a pregnant woman to her baby, and without treatment, can cause permanent blindness for a newborn is not spread by non-sexual contact like is not transmitted through surfaces and materials like toilet seats, towels, cups or you have had successful treatment for gonorrhoea before, you can still catch it NHS.
BBC News
3 days ago
- BBC News
BBC Learning English - Learning English from the News / 50% adults overweight or obese by 2050: Global study
(Photo via Getty Images) ____________________________________________________________________________ ____________________________________________________________________________ The story More than half of all adults and a third of children, teenagers and young adults around the world are predicted to be overweight or obese by 2050. The findings come from a new study of global data, covering more than 200 countries, published in The Lancet, a well-known British medical journal. Researchers warn that if trends continue, global rates of overweight and obese adults would increase significantly, particularly in Asia and Africa, where populations are growing. Experts say that if governments take urgent action now, there is still time to prevent what they describe as a "profound tragedy". News headlines How global obesity epidemic is set to get a whole lot worse South China Morning Post 'Unparalleled threat' of death: Over 50% of adults worldwide will be overweight by 2050 Wion Shocking number of Brits who will be obese by 2050 revealed in damning study The Sun Key words and phrases a whole lot very much Layla seems a whole lot happier in her new house. unparalleled there's nothing like it The new genetic technology is currently unparalleled. damning indicates something is very negative The critic gave the film a damning review. They said it was the worst movie of the year. Next If you like learning English from the news, click here.
